Unlikely. The grant would be awarded for a research plan grounded in the results we have seen. The money typically would be specifically for related research and trials, though related operation costs would probably be covered (production of drug, CRO if needed, etc.)
It would mean that we likely would be able to at a minimum run a COVID phase 2 trial.
The accompanying stock price increases and volume would take care of near term cash needs for operations, Kevetrin oral formulation, and probably a phase 2 B-IBD trial.
Of course, that validation could lead to partnerships at better terms on any of our indications at any time. A successful COVID trial could lead to a large buyout or partnership as well.
Go IPIX!
Market Data 
Markets 
